The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 18, 2020
Filed:
Jul. 30, 2016
Applicant:
Calgent Biotechnology Co., Ltd., Taipei, TW;
Inventors:
Assignee:
Calgent Biotechnology Co., Ltd., Taipei, TW;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/122 (2006.01); A61K 31/40 (2006.01); A61K 31/166 (2006.01); A61K 31/70 (2006.01); C07D 207/04 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 295/135 (2006.01); C07D 295/13 (2006.01); C07C 311/29 (2006.01); C07C 237/34 (2006.01); C07D 213/40 (2006.01); C07C 225/30 (2006.01); C07C 255/58 (2006.01); C07D 209/08 (2006.01); C07D 209/44 (2006.01); C07D 215/38 (2006.01); C07D 215/40 (2006.01); A61K 33/24 (2019.01); A61K 31/7048 (2006.01); C07C 235/54 (2006.01); A61P 25/14 (2006.01); A61P 25/28 (2006.01); A61P 3/10 (2006.01); C07C 237/48 (2006.01);
U.S. Cl.
CPC ...
C07D 207/04 (2013.01); A61K 31/122 (2013.01); A61K 31/166 (2013.01); A61K 31/40 (2013.01); A61K 31/7048 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01); A61P 3/10 (2018.01); A61P 25/14 (2018.01); A61P 25/28 (2018.01); A61P 35/00 (2018.01); C07C 225/30 (2013.01); C07C 235/54 (2013.01); C07C 237/34 (2013.01); C07C 237/48 (2013.01); C07C 255/58 (2013.01); C07C 311/29 (2013.01); C07D 209/08 (2013.01); C07D 209/44 (2013.01); C07D 213/40 (2013.01); C07D 215/38 (2013.01); C07D 215/40 (2013.01); C07D 295/13 (2013.01); C07D 295/135 (2013.01); C07C 2602/10 (2017.05);
Abstract
The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.